drugset
drugset / Trial / NCT04575818

A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059

NCT04575818 ↗

Phase 1 Terminated 32 enrolled Lakefront Biotherapeutics NV
RandomizedSequentialQuadruple-blindBasic science

Summary

The main purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of GLPG4059 in healthy volunteers after single oral administrations of GLPG4059 (SAD), compared to placebo (part 1). The effect of food (FE) (high-fat, high calorie) on the pharmacokinetics and relative bioavailability (rBA) of GLPG4059 will be assessed (part 2).

Timeline

Start
2020-09-16
Primary completion
2021-04-08
Completion
2021-04-08

Outcome

Outcome not reported

Stopped: “Development of compound has been stopped”

Drugs

EvaluationDrugModalityDoseRoute
Subject GLPG4059 Unknown — Oral

Indications

No indication recorded.